MARKET

CRDF

CRDF

Cardiff Oncology Inc
NASDAQ
3.490
+0.040
+1.16%
Opening 12:38 01/21 EST
OPEN
3.510
PREV CLOSE
3.450
HIGH
3.540
LOW
3.429
VOLUME
337.76K
TURNOVER
--
52 WEEK HIGH
6.42
52 WEEK LOW
1.440
MARKET CAP
232.15M
P/E (TTM)
-3.6764
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRDF last week (0113-0117)?
Weekly Report · 1d ago
Weekly Report: what happened at CRDF last week (0106-0110)?
Weekly Report · 01/13 11:42
Weekly Report: what happened at CRDF last week (1230-0103)?
Weekly Report · 01/06 11:52
Weekly Report: what happened at CRDF last week (1223-1227)?
Weekly Report · 12/30/2024 11:44
Weekly Report: what happened at CRDF last week (1216-1220)?
Weekly Report · 12/23/2024 11:52
Craig-Hallum Reaffirms Their Buy Rating on Cardiff Oncology (CRDF)
TipRanks · 12/17/2024 13:55
Weekly Report: what happened at CRDF last week (1209-1213)?
Weekly Report · 12/16/2024 11:53
Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +
Seeking Alpha · 12/14/2024 14:00
More
About CRDF
More
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
Recently
Symbol
Price
%Change

Webull offers Cardiff Oncology Inc stock information, including NASDAQ: CRDF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRDF stock methods without spending real money on the virtual paper trading platform.